PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Medicines Discovery Catapult, Lighthouse Labs Network, Alderley Park, Mereside, Alderley Edge, Cheshire SK10 4TG, United Kingdom.\', \'Department of Health and Social Care, 39 Victoria Street, London SW1H 0EU, United Kingdom.\', \'Department of Health and Social Care, 39 Victoria Street, London SW1H 0EU, United Kingdom; The University of Manchester, Oxford Rd, Manchester M13 9PL, United Kingdom.\', \'Medicines Discovery Catapult, Lighthouse Labs Network, Alderley Park, Mereside, Alderley Edge, Cheshire SK10 4TG, United Kingdom; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Alderley Park, Mereside, Alderley Edge, Cheshire SK10 4TG, United Kingdom. Electronic address: mark.wigglesworth@md.catapult.org.uk.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • S2352-3964(21)00333-910.1016/j.ebiom.2021.103540
?:hasPublicationType
?:journal
  • EBioMedicine
is ?:pmid of
?:pmid
?:pmid
  • 34392145
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 2.895
?:rankingScore_hIndex
  • 26
?:title
  • High throughput diagnostics and dynamic risk assessment of SARS-CoV-2 variants of concern.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34392145>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34392145>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all